Medication Review
Not sure if the medication story actually fits?
Best fit when the question is dose, timing, side effects, interactions, diagnosis fit, or what has already failed.
No. Wellbutrin is not an SSRI. Wellbutrin is a brand of bupropion, an antidepressant that acts differently from selective serotonin reuptake inhibitors such as escitalopram and sertraline.
The harder question is what you are treating. An anxiety disorder and depression with anxious symptoms can overlap, but evidence for one does not automatically answer the other.
I want the diagnosis and medication history before calling a drug a good fit. Fatigue, panic, poor concentration, or a bad experience with one antidepressant cannot make that decision by themselves.
The Fast Answer
- Wellbutrin is not FDA-approved for anxiety disorders. Wellbutrin XL is approved for major depressive disorder and prevention of seasonal depressive episodes.
- SSRI approvals are drug specific. Escitalopram has an adult generalized anxiety disorder indication. Sertraline has panic disorder and social anxiety disorder indications, among others.
- Depression trials are a separate question. Bupropion and SSRIs can improve anxious symptoms in major depression; pooled studies do not prove equal effectiveness for primary anxiety disorders.
- Side effects need their own review. Anxiety, sleep disruption, sexual changes, and weight changes deserve attention without a home switching or combination plan.
These distinctions come from the Wellbutrin XL prescribing information, the escitalopram label, the Zoloft label, and the depression studies discussed below.
Do not start, stop, taper, restart, combine, or change psychiatric medication on your own, except for the seizure emergency instruction below. The prescriber needs to review the diagnosis, current prescription, interactions, and safety history.
Not every article needs an appointment. Use this page for research. Turn it into a visit when the pattern is affecting a real medication, diagnosis, or daily-function decision.
Turn this into a visit when
- You are changing, stopping, restarting, or adding a psychiatric medication.
- Side effects are shaping the decision more than the original symptom is.
- The medication partly helps, but the diagnosis, sleep, labs, or timing still do not fit.
Bring this pattern
Available for appropriate patients in California and Arizona.
Different Drugs, Different Indications
SSRIs inhibit serotonin reuptake. Bupropion affects norepinephrine and dopamine reuptake. The Wellbutrin XL label describes its antidepressant mechanism as not fully understood. Knowing the drug class does not tell us which neurotransmitter a person is “missing” or which medication will work.
Here are selected adult U.S. labeled indications, not every possible clinical use.
| Medication | Selected labeled conditions | What that means for this comparison |
|---|---|---|
| Bupropion XL, including Wellbutrin XL | Major depressive disorder; prevention of seasonal major depressive episodes | No anxiety disorder indication |
| Escitalopram, including Lexapro | Major depressive disorder; generalized anxiety disorder | An anxiety indication specific to generalized anxiety disorder |
| Sertraline, including Zoloft | Major depressive disorder; panic disorder; social anxiety disorder; OCD; PTSD; PMDD | Several distinct indications; generalized anxiety disorder is not on this U.S. label |
The labels linked above support the table. OCD and PTSD are distinct diagnoses; listing them here does not make them interchangeable with generalized anxiety disorder or panic disorder. Off-label prescribing can be appropriate, but it needs a specific rationale and discussion of the evidence and risks.
For generalized anxiety disorder, NIMH describes psychotherapy, medication, or both, including cognitive behavioral therapy. NICE guidance recommends an SSRI when an adult with GAD chooses medication. NICE is UK guidance; its recommendations do not change U.S. FDA indications.
I do not reduce this to “tired means Wellbutrin” or “wired means SSRI.” A person can have depression, an anxiety disorder, both, or symptoms that need another explanation. Sleep, substance use, bipolar history, medical conditions, prior response, and the person's priorities all belong in the assessment.
Skim Map
Three questions for the review
What the Depression Studies Actually Found
Two often-cited analyses asked about anxiety within major depressive disorder, not treatment of primary anxiety disorders.
In one analysis, Papakostas and colleagues pooled ten randomized trials involving 2,890 participants. Bupropion and SSRIs produced comparable average improvement on the anxiety measures studied. There was no consistent difference in the time to anxiety improvement. That finding applies to the studied depression population. Papakostas et al., 2008; PMID: 17631898.
The other analysis included 2,122 participants, of whom 1,275 met its high-anxiety definition. Within that subgroup, SSRIs had a modest response advantage over bupropion. The definition was based on a depression scale's anxiety-somatization score, not a diagnosis of generalized anxiety disorder. Papakostas et al., 2008; PMID: 18605812.
My read is limited to what those studies tested. Bupropion can be a reasonable depression treatment when anxiety is also present. The research does not establish it as a replacement for treatments studied for primary anxiety disorders, and group averages cannot promise a particular person's response.
Before you keep searching
If this answer changes what you might do next, pick the next clinical question now.
Can Wellbutrin Make Anxiety Worse?
Yes. Anxiety, agitation, and insomnia are listed adverse reactions in the Wellbutrin XL prescribing information. Depression research showing average anxiety improvement does not rule out worsening in an individual. SSRIs can also cause early anxiety or agitation; NICE advises discussing this risk.
New or worsening anxiety after a medication change deserves contact with the prescriber, especially if panic, agitation, or sleep loss is disrupting daily life. You do not need to reach a severity score or wait a set number of weeks before asking for help.
Treatment benefit may take several weeks. That is a reason to plan follow-up, not a reason to wait through unsafe worsening. Track what changed, when it changed, sleep, daily function, and any missed doses. Ask the prescriber what to watch for and how to reach the team between visits.
Much less sleep without feeling tired, unusual energy, racing thoughts, impulsive behavior, or hallucinations need urgent assessment. Both bupropion and SSRI labels warn about mood activation. If symptoms are severe or you cannot stay safe, use emergency care.
Sexual Effects and Weight Need Specific Evidence
I ask about sexual function directly. Reduced desire, delayed orgasm, and other changes can affect whether someone continues treatment. Depression itself can also affect sexual function, so the timing matters.
In two eight-week randomized depression trials, Clayton and colleagues found less treatment-emergent sexual dysfunction with bupropion XL than with escitalopram. Participants had normal sexual functioning at baseline. This was a comparison with escitalopram, not a rate for every SSRI, and bupropion was not free of sexual effects. Clayton et al., 2006; PMID: 16841623.
For weight, a large 2024 observational study found modest differences in average weight change among commonly used antidepressants. Bupropion had a lower weight-gain signal than sertraline; several other drugs had higher signals. The study used health records rather than randomly assigning treatment, and incomplete follow-up, adherence, and other differences between patients limit the conclusions. Petimar et al., 2024; PMID: 38950403.
Neither finding promises weight loss, reversal of SSRI-related weight gain, or recovery of sexual function after a switch or addition. Those concerns can change a treatment discussion without determining the whole prescription.
Decision Lens
Bring the change, not just the drug name
Can Wellbutrin and an SSRI Be Combined?
Sometimes a prescriber adds bupropion to an antidepressant for depression that has not improved enough. That requires a review of benefit, adverse effects, interactions, and alternatives. There is no universal combination or starting-dose recipe.
The relevant STAR*D augmentation study was Trivedi and colleagues' 2006 trial. Adults with major depression who had not reached remission on citalopram were assigned to add bupropion SR or buspirone. The groups had similar remission rates on the primary clinician-rated measure; some symptom and tolerability measures favored bupropion. Trivedi et al., 2006; PMID: 16554526.
That study did not test primary anxiety treatment, guaranteed reversal of SSRI sexual effects, or prevention of weight gain. It also did not compare adding bupropion with simply continuing citalopram alone. A separate switching trial cannot stand in as evidence for augmentation.
I would want a clear treatment target and follow-up plan before adding another medication. More neurotransmitter targets do not automatically mean better treatment.
Safety Can Change the Choice
Bupropion has specific contraindications. These include a seizure disorder, current or prior anorexia nervosa or bulimia, and abrupt withdrawal from alcohol, benzodiazepines, barbiturates, or antiseizure medicines. The XL label also contraindicates conditions that increase seizure risk, including severe head injury, arteriovenous malformation, central nervous system tumor or infection, and severe stroke. Tell the prescriber about these histories before treatment. Wellbutrin XL label, sections 4 and 5.3.
If you have a seizure while taking bupropion, stop taking bupropion and do not restart it. Call 911 for emergency assessment. This is a specific exception to the general advice about prescriber-guided medication changes. Wellbutrin XL label, section 5.3.
Bupropion can raise blood pressure and has clinically relevant drug interactions. Combining it with other medicines containing bupropion can increase exposure and seizure risk. MAOI antidepressants and certain other medicines require special precautions or are contraindicated; the prescriber and pharmacist need the complete medication list. Wellbutrin XL label, sections 4, 5, and 7.
SSRIs have their own risks. Serotonin syndrome can occur with an SSRI alone, with greater risk when other serotonergic medicines are involved. Fever, confusion, marked agitation, muscle rigidity, or other concerning symptoms need urgent medical assessment. Bleeding risk can increase with medicines such as NSAIDs, aspirin, or anticoagulants. Zoloft label, sections 5.2 and 5.3.
Both options require review of bipolar history and monitoring for worsening depression, suicidal thoughts, and unusual mood or behavior changes. Antidepressant labels emphasize increased suicidal-thought and behavior risk in children, adolescents, and young adults, with monitoring at every age. Discuss pregnancy, pregnancy plans, or breastfeeding with the prescriber; do not make an abrupt change from this article. Wellbutrin XL prescribing information, Zoloft prescribing information.
Stopping an SSRI abruptly can cause discontinuation symptoms. Bupropion changes also belong with the prescriber. The drug, dose, duration, symptoms, and history determine the plan; there is no home taper schedule here. Zoloft label, section 5.5, Wellbutrin XL label, section 2.5.
Testing Should Answer a Clinical Question
The evaluation starts with the symptom history, medical history, current medicines, and an examination when indicated. Testing may help investigate a suspected medical contributor. It is not a universal panel every person must finish before receiving psychiatric care.
For example, thyroid disease and other medical conditions can produce symptoms that overlap with depression or anxiety. The history and examination guide which tests, if any, are useful. Testing and psychiatric treatment can proceed alongside each other when appropriate; urgent care should never wait for routine lab results. NIMH: depression, NIMH: generalized anxiety disorder.
I would bring existing results to the visit rather than order a panel from a blog. A normal result does not dismiss the symptoms. An abnormal result still needs interpretation in context.
Bring the Medication Timeline
Bring current medicines and supplements, prior trials, reasons for stopping, and what happened after each change. Include sleep, caffeine, alcohol, cannabis, and any periods of unusually high energy or reduced need for sleep. Existing lab results can help; you do not need to purchase a standard panel before requesting care.
The goal is a diagnosis, a defined treatment target, and a plan for checking benefit and harm. An online comparison cannot establish those for you.
Read how medication management works, or request a medication review with your treatment history. My initial assessment as Canybec Sulayman is 75 minutes. Horizon Peak Health provides care in California and Arizona, with telehealth available in both states; visit format and scheduling are confirmed for the appointment.
Safety: This article is educational and cannot choose or change your prescription. Except for the seizure emergency instruction above, do not start, stop, taper, restart, combine, or change psychiatric medicines without prescriber guidance. Contact the prescriber promptly about worsening symptoms or concerning side effects. For suicidal thoughts or a mental health crisis, call or text 988. If you cannot stay safe, or there is a seizure, severe allergic reaction, overdose, chest pain, severe shortness of breath, fainting, or another emergency, call 911 or go to the nearest emergency department.
References
- Papakostas GI, et al. (2008). Efficacy of bupropion and the selective serotonin reuptake inhibitors in the treatment of anxiety symptoms in major depressive disorder: a meta-analysis of individual patient data from 10 double-blind, randomized clinical trials. Journal of Psychiatric Research. DOI: 10.1016/j.jpsychires.2007.05.012. PMID: 17631898.
- Papakostas GI, et al. (2008). Efficacy of bupropion and the selective serotonin reuptake inhibitors in the treatment of major depressive disorder with high levels of anxiety (anxious depression): a pooled analysis of 10 studies. Journal of Clinical Psychiatry. DOI: 10.4088/JCP.v69n0812. PMID: 18605812.
- Clayton AH, et al. (2006). Bupropion extended release compared with escitalopram: effects on sexual functioning and antidepressant efficacy in 2 randomized, double-blind, placebo-controlled studies. Journal of Clinical Psychiatry. DOI: 10.4088/JCP.v67n0507. PMID: 16841623.
- Petimar J, et al. (2024). Medication-Induced Weight Change Across Common Antidepressant Treatments: A Target Trial Emulation Study. Annals of Internal Medicine. DOI: 10.7326/M23-2742. PMID: 38950403.
- Trivedi MH, et al. (2006). Medication augmentation after the failure of SSRIs for depression. New England Journal of Medicine. DOI: 10.1056/NEJMoa052964. PMID: 16554526.
- FDA. Wellbutrin XL prescribing information, revised November 2025.
- DailyMed. Escitalopram prescribing information and Zoloft prescribing information.
- NIMH. Generalized Anxiety Disorder: What You Need to Know and Depression.
- NICE. Generalised anxiety disorder and panic disorder in adults: management, CG113 recommendations.
Where to take this next
Care that picks up where the reading stops
Written by
Canybec Sulayman PMHNP-BC, MBA
Investigating the root causes of mental health symptoms with 19 years of ICU diagnostic rigor.
Want a plan that fits the whole picture?
Bring the symptoms, medication history, labs, sleep pattern, and questions. The goal is a clearer explanation and safer next step.
